ALK’s europæiske registreringsansøgning for tabletvaccine mod husstøvmideallergi hos børn accepteret til vurdering
January 25, 2024 07:15 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) meddelte i dag, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn er accepteret til vurdering af de...
ALK’s European registration application for house dust mite SLIT-tablet in young children accepted for review
January 25, 2024 07:15 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ACARIZAX® (house dust mite sublingual immunotherapy tablet) in young children has been accepted for review by...
ALK afslutter første del af fase 1-studie med peanuttablet
January 18, 2024 09:34 ET
|
ALK Abello
Studiet fortsætter nu i sin anden del, som forventes afsluttet senere i 2024.ALK indsender protokolændring for at udvide studiet til et fase 1-2 effektstudie. ALK (ALKB:DC / OMX: ALK B / AKBLF)...
ALK completes first part of phase 1 trial with peanut SLIT-tablet
January 18, 2024 09:34 ET
|
ALK Abello
The trial now progresses into its second part, expected to complete later in 2024. ALK to submit a protocol amendment for Phase 1-2 efficacy trial extension. ALK (ALKB:DC / OMX: ALK B /...
ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergy
January 04, 2024 08:00 ET
|
ALK Abello
– PRE-PEN® (benzylpenicilloyl polylysine injection USP) is the only FDA-approved diagnostic skin test for the evaluation of penicillin allergyi,ii – The Danish, pharmaceutical company ALK (ALKB:DC /...
ALK – Finanskalender for regnskabsåret 2024
December 20, 2023 04:45 ET
|
ALK Abello
Finanskalender 2024 for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11. januar 2024: Stilleperiode8. februar 2024: Offentliggørelse af årsrapport 202314. marts 2024 kl. 16.00: Ordinær generalforsamling...
ALK – Financial calendar for the 2024 financial year
December 20, 2023 04:45 ET
|
ALK Abello
2024 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 11 January 2024: Silent period 8 February 2024: Annual report 2023 14 March 2024 at 4.00 p.m.: Annual...
ALK udvider partnerskab med Torii i Japan
December 12, 2023 10:08 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) og selskabets japanske partner Torii Pharmaceutical Co., Ltd. (’Torii’) meddeler i dag, at de har udvidet samarbejdet og har indgået yderligere en licensaftale, der...
ALK expands partnership with Torii in Japan
December 12, 2023 10:08 ET
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) and its Japanese partner Torii Pharmaceutical Co., Ltd. ('Torii') today announced that they have expanded their collaboration and entered into an additional license...
Nine-month interim report (Q3) 2023
November 15, 2023 01:30 ET
|
ALK Abello
ALK delivers 8% revenue growth with operating profit up 128% in Q3 (unaudited) ALK saw growth in all sales regions in Q3, led by sales of tablets and SCIT. As expected, European tablet sales...